Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: Report of a randomized study. Diabetes care 2018;41:1275–1284

Hiroshi Itoh; Kenji Ueshima; Issei Komuro

doi:10.2337/dci18-0028

Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: Report of a randomized study. Diabetes care 2018;41:1275–1284

Hiroshi Itoh, Kenji Ueshima, Issei Komuro

Department of Internal Medicine (Nephrology, Endocrinology and Metabolism)

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	e145-e146
Journal	Diabetes care
Volume	41
Issue number	11
DOIs	https://doi.org/10.2337/dci18-0028
Publication status	Published - 2018 Nov 1

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialised Nursing

Access to Document

10.2337/dci18-0028

Cite this

@article{4b33ea79b0fe4e21aa73445d9f649b8e,

title = "Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: Report of a randomized study. Diabetes care 2018;41:1275–1284",

author = "Hiroshi Itoh and Kenji Ueshima and Issei Komuro",

note = "Funding Information: Acknowledgments. EDIT, Inc. (Tokyo, Japan) provided medical writing and editing. Funding and Duality of Interest. The EMPATHY study was supported by Shionogi & Co., Ltd. H.I. reports grants and personal fees from Shionogi & Co., Ltd. during the conduct of the study and grants and personal fees from Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Company, Limited, MSD K.K., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co., Ltd., and Taisho Toyama Pharmaceutical Co., Ltd.; grants from Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd., Teijin Pharma Limited, Mo-chida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K.; and personal fees from Nipro Corporation and SBI Pharmaceuticals Co., Ltd. outside the submitted work. K.U. reports other (contracted work) from Shionogi & Co., Ltd. during the conduct of the study and personal fees from Shionogi & Co., Ltd. outside the submitted work. I.K. reports personal fees from Shionogi & Co., Ltd. during the conduct of the study and grants and Funding Information: personal fees from Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, and Otsuka Pharmaceutical Co., Ltd. and grants from MSD K.K., Shionogi & Co., Ltd., GlaxoSmithKline K.K., Sanofi K.K., Genzyme Japan K.K., SumitomoDainipponPharmaCo., Ltd., Mitsubishi Tanabe Pharma Corporation, and Bristol-Myers Squibb outside the submitted work. No other potential conflicts of interest relevant to this article were reported.",

year = "2018",

month = nov,

day = "1",

doi = "10.2337/dci18-0028",

language = "English",

volume = "41",

pages = "e145--e146",

journal = "Diabetes Care",

issn = "1935-5548",

publisher = "American Diabetes Association Inc.",

number = "11",

}

TY - JOUR

T1 - Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy

T2 - Report of a randomized study. Diabetes care 2018;41:1275–1284

AU - Itoh, Hiroshi

AU - Ueshima, Kenji

AU - Komuro, Issei

N1 - Funding Information: Acknowledgments. EDIT, Inc. (Tokyo, Japan) provided medical writing and editing. Funding and Duality of Interest. The EMPATHY study was supported by Shionogi & Co., Ltd. H.I. reports grants and personal fees from Shionogi & Co., Ltd. during the conduct of the study and grants and personal fees from Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Company, Limited, MSD K.K., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co., Ltd., and Taisho Toyama Pharmaceutical Co., Ltd.; grants from Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd., Teijin Pharma Limited, Mo-chida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K.; and personal fees from Nipro Corporation and SBI Pharmaceuticals Co., Ltd. outside the submitted work. K.U. reports other (contracted work) from Shionogi & Co., Ltd. during the conduct of the study and personal fees from Shionogi & Co., Ltd. outside the submitted work. I.K. reports personal fees from Shionogi & Co., Ltd. during the conduct of the study and grants and Funding Information: personal fees from Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, and Otsuka Pharmaceutical Co., Ltd. and grants from MSD K.K., Shionogi & Co., Ltd., GlaxoSmithKline K.K., Sanofi K.K., Genzyme Japan K.K., SumitomoDainipponPharmaCo., Ltd., Mitsubishi Tanabe Pharma Corporation, and Bristol-Myers Squibb outside the submitted work. No other potential conflicts of interest relevant to this article were reported.

PY - 2018/11/1

Y1 - 2018/11/1

UR - http://www.scopus.com/inward/record.url?scp=85055147649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055147649&partnerID=8YFLogxK

U2 - 10.2337/dci18-0028

DO - 10.2337/dci18-0028

M3 - Letter

C2 - 30348847

AN - SCOPUS:85055147649

VL - 41

SP - e145-e146

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -